Advocacy intelligence hub — real-time data for patient organizations
Novartis Pharmaceuticals — PHASE2
Qilu Pharmaceutical Co., Ltd. — PHASE3
Peking Union Medical College Hospital — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — NA
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Xiao Hui Zhang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — EARLY_PHASE1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — EARLY_PHASE1
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Doptelet
(avatrombopag)Orphan drugstandardSobi, Inc.
12.1 Mechanism of Action Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation...
Xiaohui Zhang, MD
Peking University People's Hospital
📍 TAMPA, FL
Carlo Visco, MD
AOU Integrata di Verona - U.O. Ematologia -Verona -Italy
Xiaohui Zhang, MD, MD
Peking University People's Hospital
📍 Beijing, FL
Abdulgabar Salama, MD
Universitätsklinikum Charite, Med. Fakultät der Humboldt-Universität Berlin
Mirella Calcinai, MD
Medical Director, Clinical Development
Heng Mei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology